Results of the phase 3 ATLAS trial revealed a potential new standard of care, according to researchers.
The retrospective analysis included 144 patients in three Australian health care facilities with a total of 539 episodes of high-dose methotrexate.
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
“Excellent” overall survival is achievable with currently available drugs, according to researchers.
The careful consideration of cancer risk is especially important during the first year after the presentation of pruritus.